Patients required a reduction in loop diuretic dose, which was also reported in the REFORM trial (Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodelling in Patients With Heart Failure and Diabetes Mellitus).23 After cessation of empagliflozin, some patients also noted increasing congestion requiring an increase in loop diuretic or had a HF hospitalization, although our trial was clearly not powered for clinical outcomes. The gene discussed is SLC5A2; the disease is hydrops fetalis.